Influenza virus vaccine Begrivac - CSLAlternative Names: Begrivac; Influenza-virus-vaccine-Begrivac-CSL
Latest Information Update: 19 Sep 2015
At a glance
- Originator Chiron
- Developer CSL
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis